



Kansas State University Innovation Partners TECHNOLOGY LICENSING PROFILE

SARS-coronavirus 2 Subunit Vaccine Candidate

INVENTOR(S): WAITHAKA MWANGI, HULDAH C. SANG

REF. NO.
2020-054-3

Description:

The coronavirus disease 2019 (COVID-19), caused by the novel pathogenic SARS-coronavirus 2 that broke out in Wuhan China, is rapidly spreading globally but there is no treatment or vaccine available. Consequently, there is an urgent need to develop safe and effective vaccines to protect the human population. Kansas State University Researchers have created a prototype vaccine candidates for induction of neutralizing antibodies against the pathogenic SARS-coronavirus 2. This vaccine is a nucleic acid based vaccine. It has been validated with antibody tests and can be scaled up right away as needed and then tested for its ability to induce neutralizing antibodies against SARS-coronavirus 2.

Advantages:

- Capable of inducing protective neutralizing antibodies against the novel pathogenic SARS-coronavirus 2 (2019-nCoV)
- Safe and effective vaccine to manage and control spread of the disease

Applications:

- SARS-coronavirus 2 (2019-nCoV) Vaccine

Patent Status: Pending